ClinicalTrials.gg
RecruitingNCT05865327UNPINUpdated Sep 12, 2025

UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture

An interventional study of Cryoneurolysis and Sham Cryoneurolysis in Rib Fractures, Rib Fracture Multiple and Rib; Fracture, With Flail Chest, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Traumatic rib fractures (i.e., broken ribs caused by a physical injury) are common and very painful. They also often lead to serious complications, more time spent in hospital, and can even lead to death. Even after rib fractures have healed, they can lead to long-term pain and a lower quality of life.

A technology called cryoneurolysis, which acts to freeze nerves causing pain using a small tool which can turn very cold, is a promising new way to manage rib fracture pain. This study is a test with a small number of people to see if it is feasible to use this technology for patients with rib fractures. If this is successful, we will recruit more people for a larger study to see if cryoneurolysis, along with standard pain control techniques, is better at stopping pain, compared to just the normal techniques alone. Participants in our study will be asked to rate their pain, and record pain medications that they take for 3 months after their pain procedure.

Read the detailed description

More than 100,000 people a year suffer from traumatic rib fractures. Pain from rib fractures impairs the ability to inspire deeply and cough effectively, predisposing patients to severe, potentially life threatening complications and increased healthcare costs. For many patients, this pain can also persist long after the acute injury has healed, delaying recovery and reducing quality of life.

Current pain interventions, including multimodal analgesia and local anesthetic-based nerve blocks, are useful, but are limited by a short duration of effectiveness, and/or risk of complications. Cryoneurolysis (CN) is a new method to control pain which acts to freeze intercostal nerves (ICNs) associated with fractured ribs using a handheld device. This freezing action causes neurons to undergo Wallerian degeneration distally from the site of ablation and thus exhibit an extended but reversible block.

This study is a single-site, randomized, pilot study to assess the feasibility of recruitment, randomization, and protocol adherence of providing cryoneurolysis for patients with traumatic rib fractures. Secondary data from the pilot trial designed to assess the effectiveness of the intervention (pain scores, opioid usage, etc.) will be included in the analysis of the full trial if feasible. The objective of the full trial is to demonstrate that cryoneurolysis of ICN, in addition to standard analgesic practice, provides superior, prolonged analgesia.

Participants (individuals aged 18-85, with 3-8 unilateral traumatic rib fractures) will be randomized 1:1 in blocks of 4, stratified by number of rib fractures (> 4 or ≤4) and the presence/absence of flail segment, to receive the current standard of practice for rib fractures (multimodal analgesia and erector spinae plane (ESP) catheter infusion) with or without the addition of CN. Participants in the standard care group will receive a sham CN procedure to maintain blinding.

All participants (both groups) will receive standard of care analgesia. Specifically, an ultrasound-guided ESP catheter will be placed as per standard protocols. 20cc of 0.5% ropivacaine and 1% lidocaine will be injected through the catheter, followed by a basal infusion of 2 cc/hr of 0.2% ropivacaine (to maintain catheter patency) with an on demand patient controlled regional anesthesia (PCRA) dose of 10cc 0.2% ropivacaine available hourly until patient has met criteria for APS discharge or pain is controlled such that PCRA use is \< 2 boluses over 12 hrs and NRS \< 3 with deep breathing and coughing.

Standard multimodal analgesia including Tylenol 1000mg QID, Celebrex 200mg BID (or ketorolac 7.5 QID), Pregabalin 50mg BID, and/or PRN oral hydromorphone (1-4mg) will also be provided. Additional analgesics include intravenous ketamine at a dose of 0.1-0.2 mg/kg/hr of lean body weight in the event of consistent NRS pain scores > 6, and up to 0.05 mg/kg of intravenous midazolam for anxiolysis and 1mcg/kg of intravenous fentanyl for comfort during positioning, as required.

Participants will remain in the study for 3 months from the date of the block procedure. They will be followed daily while in hospital and using a pain diary following discharge (weekly pain scores and daily opioid usage). Additionally, follow-ups will be completed at 1h, 24h, 48h, 1 week, 1 month, and 3 months post block procedure.

02

Conditions studied

  • Rib Fractures
  • Rib Fracture Multiple
  • Rib; Fracture, With Flail Chest
  • Pain
  • Pain, Acute
  • Pain, Chronic
  • Trauma
  • Trauma Injury

Keywords

  • Cryoneurolysis
  • Rib Fracture Pain
  • Intercostal Nerve Block
03

In context

Rib Fractures

126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.

This study's planned enrollment of 24 is below the median of 60 across 92 interventional studies indexed under Rib Fractures.

Browse Rib Fractures studies →

Lead sponsor

Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 135 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18
  • Unilateral traumatic rib fractures (3 to 8)
  • Candidate for ESP block catheter
  • Within 48hrs of admission to hospital

Exclusion criteria

Exclusion Criteria:

  • Lack of patient consent; unlikely to comply with follow up
  • Unable to use Patient Controlled Regional Analgesia (Ventilated/sedated patients or Moderate to severe traumatic brain injury)
  • Chronic pain (opioid use > 30mg oral morphine equivalent per day)
  • Substance use disorder
  • \< 50
  • > 45
  • Significant distracting injuries (unreduced long bone fractures, unstable pelvic or spine fractures and patients requiring trauma laparotomy- also preclude positioning for block placement (lateral decubitus or sitting up))
  • for ESP catheter placement (pre-existing medical/neurological/hematologic diseases, localized infection/trauma at site of intervention, allergy to amide local anesthetics)
  • Contraindications to CN (cryoglobulinemia, paroxysmal cold hemoglobinuria, multiple myeloma and cold urticarial).
  • Unable to return to Trauma Recovery Clinic (in-person or virtual) at 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cryoneurolysis Group

    In addition to all standard of care analgesia treatments, CN will be performed on the ICN of each broken rib using the Iovera CN device and Generation 2 Iovera tip under ultrasound guidance.

    Procedure: Cryoneurolysis

  • Sham comparator
    Standard Care Group

    Participants in the control group will receive all standard of care analgesia treatments as well as sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding.

    Procedure: Sham Cryoneurolysis

Interventions

  • ProcedureCryoneurolysis

    Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.

  • ProcedureSham Cryoneurolysis

    Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.

06

What researchers measure

Primary outcomes

  1. Number of participants randomized over an 8 month period

    Goal of 3 participants per month for 8 months

    Time frame: Entire pilot study (approximately 8 months)

  2. Number of participants able to adhere to the protocol

    Goal of \> 90%

    Time frame: Entire pilot study (approximately 8 months + 3 month follow-up)

  3. Number of participants able to adhere to the follow-up

    Goal of \> 90%

    Time frame: 3 month follow-up

  4. Rate of Adverse events

    Ensure no adverse events (short or long term) associated with CN

    Time frame: 3 month follow-up

Secondary outcomes

  1. Pain Severity during deep inspiration 24 hours post ESP catheter placement

    Pain measured using Numeric Pain Rating Scale

    Time frame: 24 hours post placement of ESP catheter

  2. Time to discontinuation of ESP catheter

    Based on when patient has met criteria for APS discharge or pain is controlled such that PCRA use is \< 2 boluses over 12 hrs and NRS \< 3 with deep breathing and coughing

    Time frame: Until ESP catheter removal (usually < 7 days)

  3. ESP catheter use

    Cumulative volume of local anesthetic solution used via ESP catheter patient controlled reginal analgesia

    Time frame: Until ESP catheter removal (usually < 7 days)

  4. Opioid consumption in hospital and after discharge

    Determined from medical records (in-hospital) and via a daily pain diary (post-discharge). Calculated in Oral Morphine Equivalents.

    Time frame: Daily for 90 days after block placement

  5. Pain Intensity at 1 and 3 months

    As measured using Numeric Pain Rating Scale (0-10) , at rest and during deep inspiration

    Time frame: 1 and 3 month follow-ups

  6. Oxygen requirements

    Room air oxygen saturation (SpO2) and requirement for supplementary O2 to maintain SpO2 \> 92%

    Time frame: Pre-intervention, post intervention, then daily until discharge

  7. Pulmonary Function Testing

    FVC

    Time frame: Pre-intervention, post intervention, then daily until discharge

  8. Pulmonary Function Testing

    FEV1

    Time frame: Pre-intervention, post intervention, then daily until discharge

  9. Pulmonary Function Testing

    Peak Inspiratory flow

    Time frame: Pre-intervention, post intervention, then daily until discharge

  10. Pulmonary Function Testing

    Peak Expiratory Flow

    Time frame: Pre-intervention, post intervention, then daily until discharge

  11. Length of Stay in hospital

    Hospital discharge date

    Time frame: Date of admission to date discharge

  12. Length of Stay on acute pain service (APS)

    Criteria include on oral meds without continuous regional analgesia or intravenous opioids

    Time frame: Date of admission to date of discharge from acute pain service

  13. Time to achieve discharge criteria for isolated chest injury

    Criteria include on oral meds without continuous regional analgesia, chest tube out and chest well evacuated (e.g. no evidence of retained hemothorax), and no supplemental O2

    Time frame: Date of admission until discharge criteria met

  14. Patient satisfaction

    Patient satisfaction assessed using Patients' Global Impression of Change (PGIC) scale

    Time frame: 48 post block procedure, and 1 week, 1 month and 3 month follow-ups

  15. Incidence of chronic rib fracture pain

    As assessed using Brief Pain Inventory (BPI) questionnaire

    Time frame: 3 month follow-up

  16. Adverse events

    Adverse events to be recorded include: local anesthetic complications, catheter related complications (clotting, migration), procedural complications (pneumothorax, bleeding, infection), and neurological disturbances (dysesthesia, hyperalgesia, allodynia) in area of rib fracture

    Time frame: until 3 month follow-up

Other outcomes

  1. Pain Intensity

    As measured using NRS-11, at rest and during deep inspiration

    Time frame: 1h and 48h, post block placement, daily in hospital, weekly post discharge and at 1 week follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant-level data will be made available upon reasonable request to study PI following publication of full trial results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: This is a pilot trial and full inferential analysis will not be conducted until completion of the full trial. As such, data will be available following publication of the primary results of the subsequent full trial.

Access criteria: Data and supporting information will be made available following reasonable request directly to study PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.

Of 41 non-industry interventional studies with no phase under Rib Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's planned 26 months is above that.

Counting every sponsor, half of 41 studies reached it within 23 months; a quarter within 15 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 18, 2023
StartActual
Oct 23, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05865327
Responsible party
Sponsor
First posted
May 18, 2023
Start date
Oct 23, 2023
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Sep 12, 2025

Study contacts

Ben Safa, MD
Contact
ben.safa@sunnybrook.ca
416-480-4864
Ben Safa, MD
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion